Activator protein 1 promotes gemcitabine‑induced apoptosis in pancreatic cancer by upregulating its downstream target bim

Oncology Letters

Volumn 12, Issue 6, 2016, Pages 4732-4738

  Ren, Xiaoxia ^a   Zhao, Wenjing ^a   Du, Yongxing ^a   Zhang, Taiping ^a   You, Lei ^a   Zhao, Yupei ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIM PROTEIN; GEMCITABINE; TRANSCRIPTION FACTOR AP 1;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PANCREAS CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL TIME; TUNEL ASSAY; UPREGULATION; WESTERN BLOTTING;

EID: 84995784804     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2016.5294     Document Type: Article

References (41)

1. Jones OP, Melling JD and Ghaneh P: Adjuvant therapy in pancreatic cancer. World J Gastroenterol 20: 14733-14746, 2014.
2. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
3. Silvestris N, Gnoni A, Brunetti AE, Vincenti L, Santini D, Tonini G, Merchionne F, Maiello E, Lorusso V, Nardulli P, et al: Target therapies in pancreatic carcinoma. Curr Med Chem 21: 948-965, 2014.
4. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, et al: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364: 1817-1825, 2011.
5. Thota R, Pauff JM and Berlin JD: Treatment of metastatic pancreatic adenocarcinoma: a review. Oncology (Williston Park) 28: 70-74, 2014.
6. Rocha Lima CM, Green MR, Rotche R, Miller WH Jr, Jeffrey GM, Cisar LA, Morganti A, Orlando N, Gruia G and Miller LL: Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 22: 3776-3783, 2004.
7. Xu J, Wang T, Cao Z, Huang H, Li J, Liu W, Liu S, You L, Zhou L, Zhang T and Zhao Y: MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis. Oncotarget 5: 6983-6993, 2014.
8. Al-Hajeili M, Azmi AS and Choi M: Nab-paclitaxel: potential for the treatment of advanced pancreatic cancer. Onco Targets Ther 7: 187-192, 2014.
9. Chiorean EG and Von Hoff DD: Taxanes: impact on pancreatic cancer. Anticancer Drugs 25: 584-592, 2014.
10. Sherman MH, Yu RT, Engle DD, Ding N, Atkins AR, Tiriac H, Collisson EA, Connor F, Van Dyke T, Kozlov S, et al: Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell 159: 80-93, 2014.
11. Liu Z, Li D, Zheng X, Wang E and Wang J: Selective induction of apoptosis: promising therapy in pancreatic cancer. Curr Pharm Des 19: 2259-2268, 2013.
12. Bianco R, Melisi D, Ciardiello F and Tortora G: Key cancer cell signal transduction pathways as therapeutic targets. Eur J Cancer 42: 290-294, 2006.
13. Nicholson DW: From bench to clinic with apoptosis-based therapeutic agents. Nature 407: 810-816, 2000.
14. Zhao C, Qiao Y, Jonsson P, Wang J, Xu L, Rouhi P, Sinha I, Cao Y, Williams C and Dahlman-Wright K: Genome-wide profiling of AP-1-regulated transcription provides insights into the invasiveness of triple-negative breast cancer. Cancer Res 74: 3983-3994, 2014.
15. Shaulian E: AP-1-the Jun proteins: oncogenes or tumor suppressors in disguise? Cell Signal 22: 894-899, 2010.
16. Chinenov Y and Kerppol TK: Close encounters of many kinds: Fos-Jun interactions that mediate transcription regulatory specificity. Oncogene 20: 2438-2452, 2001.
17. Kolbus A, Herr I, Schreiber M, Debatin KM, Wagner EF and Angel P: c-Jun-dependent CD95-L expression is a rate-limiting step in the induction of apoptosis by alkylating agents. Mol Cell Biol 20: 575-582, 2000.
18. Ren X, Song W, Liu W, Guan X, Miao F, Miao S and Wang L: Rhomboid domain containing 1 inhibits cell apoptosis by upregulating AP-1 activity and its downstream target Bcl-3. FEBS Lett 587: 1793-1798, 2013.
19. Shi R, Peng H, Yuan X, Zhang X, Zhang Y, Fan D, Liu X and Xiong D: Down-regulation of c-fos by shRNA sensitizes adriamycin-resistant MCF-7/ADR cells to chemotherapeutic agents via P-glycoprotein inhibition and apoptosis augmentation. J Cell Biochem 114: 1890-1900, 2013.
20. Leijen S, Veltkamp SA, Huitema AD, van Werkhoven E, Beijnen JH and Schellens JH: Phase I dose-escalation study and population pharmacokinetic analysis of fixed dose rate gemcitabine plus carboplatin as second-line therapy in patients with ovarian cancer. Gynecol Oncol 130: 511-517, 2013.
21. Meng Q and Xia Y: c-Jun, at the crossroad of the signaling network. Protein Cell 2: 889-898, 2011.
22. Passegué E, Jochum W, Schorpp-Kistner M, Möhle-Steinlein U and Wagner EF: Chronic myeloid leukemia with increased granulocyte progenitors in mice lacking junB expression in the myeloid lineage. Cell 104: 21-32, 2001.
23. Kashatus D, Cogswell P and Baldwin AS: Expression of the Bcl-3 proto-oncogene suppresses p53 activation. Genes Dev 20: 225-235, 2006.
24. Li J, Liang X and Yang X: Ursolic acid inhibits growth and induces apoptosis in gemcitabine-resistant human pancreatic cancer via the JNK and PI3K/Akt/NF-κB pathways. Oncol Rep 28: 501-510, 2012.
25. Dai MH, Liu SL, Chen NG, Zhang TP, You L, Q Zhang F, Chou TC, Szalay AA, Fong Y and Zhao YP: Oncolytic vaccinia virus in combination with radiation shows synergistic antitumor efficacy in pancreatic cancer. Cancer Lett 344: 282-290, 2014.
26. Chugh R, Sangwan V, Patil SP, Dudeja V, Dawra RK, Banerjee S, Schumacher RJ, Blazar BR, Georg GI, Vickers SM and Saluja AK: A preclinical evaluation of Minnelide as a therapeutic agent against pancreatic cancer. Sci Transl Med 4: 156ra139, 2012.
27. Trouilloud I, Dubreuil O, Boussaha T, Lepère C, Landi B, Zaanan A, Bachet JB and Taieb J: Medical treatment of pancreatic cancer: new hopes after 10 years of gemcitabine. Clin Res Hepatol Gastroenterol 35: 364-374, 2011.
28. Lee JG and Wu R: Erlotinib-cisplatin combination inhibits growth and angiogenesis through c-MYC and HIF-1α in EGFR-mutated lung cancer in vitro and in vivo. Neoplasia 17: 190-200, 2015.
29. Elmore S: Apoptosis: a review of programmed cell death. Toxicol Pathol 35: 495-516, 2007.
30. Evans GL and Vousden KH: Proliferation, cell cycle and apoptosis in cancer. Nature 411: 342-348, 2001.
31. Bu HQ, Luo J, Chen H, Zhang JH, Li HH, Guo HC, Wang ZH and Lin SZ: Oridonin enhances antitumor activity of gemcitabine in pancreatic cancer through MAPK-p38 signaling pathway. Int J Oncol 41: 949-958, 2012.
32. Teraishi F, Zhang L, Guo W, Dong F, Davis JJ, Lin A and Fang B: Activation of c-Jun NH2-terminal kinase is required for gemcitabine’s cytotoxic effect in human lung cancer H1299 cells. FEBS Lett 579: 6681-6687, 2005.
33. Yang XL, Lin FJ, Guo YJ, Shao ZM and Ou ZL: Gemcitabine resistance in breast cancer cells regulated by PI3K/AKT-mediated cellular proliferation exerts negative feedback via the MEK/MAPK and mTOR pathways. Onco Targets Ther 7: 1033-1042, 2014.
34. Wang H, Yang YB, Shen HM, Gu J, Li T and Li XM: ABT-737 induces Bim expression via JNK signaling pathway and its effect on the radiation sensitivity of HeLa cells. PLoS One 7: e52483, 2012.
35. Rebollo A, Dumoutier L, Renauld JC, Zaballos A, Ayllón V and Martínez A C: Bcl-3 expression promotes cell survival following interleukin-4 deprivation and is controlled by AP1 and AP1-like transcription factors. Mol Cell Biol 20: 3407-3416, 2000.
36. Wang W, Du Z, Yan J, Ma D, Shi M, Zhang M, Peng C and Li H: Mesenchymal stem cells promote liver regeneration and prolong survival in small-for-size liver grafts: involvement of C-Jun N-terminal kinase, cyclin D1, and NF-κB. PLoS One 9: e112532, 2014.
37. Niu Q, Liu H, Guan Z, Zeng Q, Guo S, He P, Guo L, Gao P, Xu B, Xu Z, et al: The effect of c-Fos demethylation on sodium fluoride-induced apoptosis in L-02 cells. Biol Trace Elem Res 149: 102-109, 2012.
38. Renaud SJ, Kubota K, Rumi MA and Soares MJ: The FOS transcription factor family differentially controls trophoblast migration and invasion. J Biol Chem 289: 5025-5039, 2014.
39. Ganesan V and Colombini M: Regulation of ceramide channels by Bcl-2 family proteins. FEBS Lett 584: 2128-2134, 2010.
40. Smith SC, Petrova AV, Madden MZ, Wang H, Pan Y, Warren MD, Hardy CW, Liang D, Liu EA, Robinson MH, et al: A gemcitabine sensitivity screen identifies a role for NEK9 in the replication stress response. Nucleic Acids Res 42: 11517-11527, 2014.
41. Gautam S, Kirschnek S, Wiesmeier M, Vier J and Häcker G: Roscovitine-induced apoptosis in neutrophils and neutrophil progenitors is regulated by the Bcl-2-family members Bim, Puma, Noxa and Mcl-1. PLoS One 8: e79352, 2013.